A Strategy for Risk Management of Drug-Induced Phospholipidosis

Toxicologic Pathology

Volumn 37, Issue 7, 2009, Pages 997-1005

  Chatman, Linda A ^a   Morton, Daniel ^a   Johnson, Theodore O ^a   Anway, Susan D ^a  

^a PFIZER INC   (United States)

Author keywords

drug induced phospholipidosis; phospholipidosis strategy; risk management

Indexed keywords

AMIODARONE; CHLOROQUINE; GENTAMICIN; HEXESTROL BIS(2 DIETHYLAMINOETHYL) ETHER; TELITHROMYCIN;

BIOAVAILABILITY; COMPUTER MODEL; DRUG DESIGN; DRUG INDUCED DISEASE; DRUG LABELING; DRUG MARKETING; DRUG SAFETY; ELECTRON MICROSCOPY; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPIDOSIS; LIPOPHILICITY; MICROSCOPY; PATIENT SAFETY; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK MANAGEMENT; STRUCTURE ACTIVITY RELATION;

COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG TOXICITY; HUMANS; LIPIDOSES; LUNG; LYSOSOMES; PHOSPHOLIPIDS; RISK MANAGEMENT;

ANIMALIA;

EID: 74949133999     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/0192623309352496     Document Type: Article

References (40)

1. Baronas ET Lee J Alden C Hsieh F Biomarkers to monitor drug-induced phospholipidosis Toxicol Appl Pharmacol 2006 218 72 78
2. Berridge BR Chatman LA Odin M Schultze AE Losco PE Meehan JT Peters T Vonderfecht SL Letter to the Editor Toxicol Pathol 2007 35 325
3. Cavagnaro JA Cavagnaro JA The principles of ICH S6 and the case-by-case approach Preclinical Safety Evaluation of Biopharmaceuticals: A Science-Based Approach to Facilitating Clinical Trials 2008 Hoboken, NJ John Wiley and Sons, Inc 45 65
4. Cornett DS Frappier SL Caprioli RM MALDI-FTICR imaging mass spectrometry of drugs and metabolites in tissue Anal Chem 2008 80 5648 53
5. Fischer H Kansy M Bur D CAFCA: A novel tool for the calculation of amphiphilic properties of charged drug molecules Chimia 2000 54 640 45
6. Halstead BW Zwicki CM Morgan RE Monteith DK Thomas CE Bowers RK Berridge BR A clinical flow cytometric biomarker strategy: Validation of peripheral leukocyte phospholipidosis using nile red J Appl Toxicol 2006 26 169 77
7. Halliwell WH Cationic amphiphilic drug-induced phospholipidosis Toxicol Pathol 1997 25 53 60
8. Hostetler KY Molecular studies of the induction of cellular phospholipidosis by cationic amphiphilic drugs Fed Proc 1984 43 2582 85
9. Huterer S Wherrett J Metabolism of bis(monoacylglycero)phosphate in macrophages J Lipid Res 1979 20 966 73
10. Jessurun GA Boersma WG Crijns HJ Amiodarone-induced pulmonary toxicity. Predisposing factors, clinical symptoms and treatment Drug Saf 1998 18 339 44
11. Kacew S Cationic amphiphilic drug-induced renal cortical lysosomal phospholipidosis: An in vivo comparative study with gentamicin and chlorphentermine Toxicol Appl Pharmacol 1987 91 469 76
12. Kodavanti UP Mehendale HM Cationic amphiphilic drugs and phospholipid storage disorder Pharmacol Rev 1990 42 327 54
13. Kruhlak NL Choi SS Contrera JF Weaver JL Willard JM Hastings KL Sancilio LF Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models Toxicol Mech Methods 2008 18 217 27
14. Lüllmann-Rauch R Drug induced lysosomal disorders Front Biol 1979 48 49 130
15. Matsuzawa Y Yokomura T Ishikawa K Adachi S Yamamoto A Studies on drug-induced lipidosis. VI. Identification and determination of the drug and its metabolite in lipidosis induced by 4, 4′-diethyl-aminoethoxyhexestrol J Biochem (Tokyo) 1972 72 615 21
16. Monteith DK Morgan RE Halstead B In vitro assays and biomarkers for drug-induced phospholipidosis Expert Opin Drug Metab Toxicol 2006 2 687 96
17. Morelli JK Buehrle M Pognan F Barone LR Fieles W Ciaccio PJ Validation of an in vitro screen for phospholipidosis using a high-content biology platform Cell Biol Toxicol 2006 22 15 27
18. Mortuza GB Neville WA Delaney J Waterfield CJ Camilleri P Characterization of a potential biomarker of phospholipidosis from amiodarone-treated rats Biochim Biophys Acta 2003 1631 136 46
19. Nicholls AW Nicholson JK Haselden JN Waterfield CJ A metabonomic approach to the investigation of drug-induced phospholipidosis: An NMR spectroscopy and pattern recognition Biomarkers 2000 5 410 23
20. Pauluhn J Pulmonary irritant potency of polyisocyanate aerosols in rats: Comparative assessment of irritant threshold concentrations by bronchoalveolar lavage J Appl Toxicol 2004 24 231 47
21. Pelletier DJ Gelhaar DJ Tilloy-Ellul A Johnson TO Greene NJ Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential J Chem Inf Model 2007 47 1197 205
22. Piccotti JR LaGattuta MS Knight SA Gonzales AJ Bleavins MR Induction of apoptosis by the cationic amphiphilic drugs amiodarone and imipramine Drug Chem Toxicol 2005 28 117 33
23. Ploemen JP Kelder J Hafmans T van de Sandt H van Burgsteden JA Salemink JMS van Esch E Use of physiochemical calculation of pKa and clogP to predict phospholipidosis-inducing potential J Exp Toxicol Pathol 2004 55 347 55
24. Reasor MJ Hastings KL Ulrich RG Drug-induced phospholipidosis: Issues and future directions Expert Opin Drug Saf 2006 5 567 83
25. Reasor MJ Kacew S Drug-induced phospholipidosis: Are there functional consequences? Exp Biol Med 2001 226 825 30
26. Reasor MJ McCloud CM Beard TL Ebert DC Kacew S Gardner MF Aldern KA Hostetler KY Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer-344 and Sprague-Dawley rats Toxicology 1996 106 139 47
27. Reasor MJ Ogle CL Walker ER Kacew S Amiodarone-induced phospholipidosis in rat alveolar macrophages Am Rev Respir Dis 1988 137 510 18
28. Sawada H Takami K Asahi S A toxicogenomic approach to drug-induced phospholipidosis: Analysis of its induction mechanism and establishment of a novel in vitro screening system Toxicol Sci 2005 83 282 92
29. Scuntaro I Kientsch U Weismann UN Honegger UE Inhibition by vitamin E of drug accumulation and of phospholipidosis induced by desipramine and other cationic amphiphilic drugs in human cultured cells Br J Pharmacol 1996 119 829 34
30. Shikata T Kanetaka T Endo Y Nagashima K Drug-induced generalized phospholipidosis Acta Pathol Jap 1972 22 517 33
31. Siddiqui AK Huberfeld SI Weidenheim KM Einberg KR Efferen LS Hydroxychloroquine-induced toxic myopathy causing respiratory failure Chest 2007 131 588 90
32. Stebbins KE Bond DM Novilla MN Reasor MJ Spino-sad insecticide: Subchronic and chronic toxicity and lack of carcinogenicity in CD-1 mice Toxicol Sci 2002 65 276 87
33. Tilloy A Vidal L Masson M-T 2002 Drug-induced phospholipidosis assessed in both human and rat in vitro lymphocyte models. Molecular and Cellular Toxicology Laboratory and Pathology Department, Pfizer Global R&D Safety Sciences Internal validation report.
34. Tulkens PM Experimental studies on nephrotoxicity of aminoglycosides at low doses. Mechanism and perspectives Am J Med 1986 80 105 14
35. Turner M Corey RG Abruty E Telithromycin Ann Intern Med 2006 144 447 48
36. Ulrich RG Kilgore KS Sun EL Cramer CT Ginsberg LC An in vitro fluorescence assay for the detection of drug-induced cytoplasmic lamellar bodies Toxicol Methods 1991 12 89 105
37. Vonderfecht SL Stone ML Eversole RR Yancey MF Schuette MR Duncan BA Ware JA Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence Toxicol Pathol 2004 32 318 25
38. Willard J FDA Phospholipidosis Working Group, Preliminary results and developing opinions [abstract] 2008 Society of Toxicological Pathology, 27th Annual Symposium San Francisco, CA
39. Xia Z Gu Y Hansson AL Karlsson H Xie Y Bergstrandt A DePierre JW Nassberger L Antidepressant-induced lipidosis with special reference to tricyclic compounds Prog Neurobiol 2000 60 501 12
40. Yamamoto A Adachi S Ishikawa K Yokomura T Kitani T Studies on drug-induced lipidosis. 3. Lipid composition of the liver and some other tissues in clinical cases of “Niemann-Pick-like syndrome” induced by 4, 4′-diethylaminoethoxyhexestrol J Biochem (Tokyo) 1971 70 775 84